I
Ian Chopra
Researcher at University of Leeds
Publications - 159
Citations - 13589
Ian Chopra is an academic researcher from University of Leeds. The author has contributed to research in topics: Antibacterial agent & Escherichia coli. The author has an hindex of 56, co-authored 159 publications receiving 12349 citations. Previous affiliations of Ian Chopra include University of Ljubljana & British Society for Antimicrobial Chemotherapy.
Papers
More filters
Journal ArticleDOI
Prospects for Aminoacyl-tRNA Synthetase Inhibitors as New Antimicrobial Agents
TL;DR: Recent novel findings in the laboratory suggest that AaRS could represent therapeutic targets where the loss of fitness associated with resistance could be compatible with antimicrobial restriction policies to eliminate resistance.
Journal ArticleDOI
The search for antimicrobial agents effective against bacteria resistant to multiple antibiotics.
TL;DR: This minireview reviews the status of research in this critical therapeutic area, reevaluate the potential of older, unexploited agents and review current approaches to the discovery of new agents, including the identification of new molecular targets for antibiotic action.
Journal ArticleDOI
Effect of short-chain organic acids on macromolecular synthesis in Escherichia coli.
TL;DR: Growing cultures of Escherichia coli with propionic acid or formic acid at pH 5.0 produced bacteriostasis lasting 30 and 120 min respectively, and growth resumed after continued incubation in the presence of acid, but cells from acid-treated cultures were larger than controls.
Journal ArticleDOI
New developments in tetracycline antibiotics: glycylcyclines and tetracycline efflux pump inhibitors.
TL;DR: The tetracyclines, discovered in the 1940s, are a well-established class of antibiotics that still have a role in treating microbial infections in man but the widespread emergence of bacterial resistance due to efflux and ribosomal protection mechanisms has severely limited their effectiveness.
Journal ArticleDOI
Structure-based discovery of antibacterial drugs
TL;DR: This Review explores the exciting opportunities for antibacterial-drug discovery arising from structure-based drug design and suggests that novel modes of action will be vital to meet the threats created by the emergence of resistance.